Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Bioorganic & Medicinal Chemistry|September 1, 1996
Discovery and optimization of nonpeptide HIV-1 protease inhibitorsP J Tummino, J V Prasad, D Ferguson, et al.
British Journal of Haematology|October 6, 2004
Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'Andrés J M Ferreri, Elías Campo, John F Seymour, et al.
Leukemia|March 27, 2009
Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplantP N Hari, M-J Zhang, V Roy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2006
Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trialsJ Franklin, A Pluetschow, M Paus, et al.
Journal of Medicinal Chemistry|November 26, 1997
4-hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV proteaseB D Tait, S Hagen, J Domagala, et al.
Leukemia & Lymphoma|August 9, 2020
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaGraeme A M Fraser, Asher Chanan-Khan, Fatih Demirkan, et al.
Leukemia|April 23, 2010
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and managementR A Kyle, B G M Durie, S V Rajkumar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's diseaseJ L Gajewski, G L Phillips, K A Sobocinski, et al.
Leukemia|October 14, 2018
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaG Fraser, P Cramer, F Demirkan, et al.
Blood Advances|September 18, 2023
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphomaLoretta J Nastoupil, Georg Hess, Miguel A Pavlovsky, et al.
Pageof 9